Enhanced chimeric antigen receptor t cell composition and method of use

WO2025241005A1PCT designated stage Publication Date: 2025-11-27COUNCIL OF THE QUEENSLAND INST OF MEDICAL RES
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/AU2025/050536
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-05-22
Filing Date
2025-05-22
Publication Date
2025-11-27

Smart Images

  • Figure AU2025050536_27112025_PF_FP_ABST
    Figure AU2025050536_27112025_PF_FP_ABST
Patent Text Reader

Abstract

Disclosed herein are therapeutic compositions that comprise a population of T cells that express chimeric antigens (CAR T cells) specific for a cancer or tumour antigen and are capable or binding to a collection of epitopes derived from cytomegalovirus (CMV), and methods of treating cancer with the use of therapeutic compositions. Also disclosed are antigenic peptides derived from CMV, that are useful in the manufacture of improved CAR T cells. More specifically, disclose herein are uses and methods of treating diseases and conditions, including cancer.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Bi-specific targeted chimeric antigen receptor t cells

    WO2016154628A1

  • Adoptive t-cell therapy for CMV infection and CMV-associated diseases

    WO2019220209A1

  • Targeting EPHA3 and uses thereof

    WO2021068040A1